Advertisement
UK markets closed

  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

  • HANG SENG

    17,201.27
    +372.34 (+2.21%)
     

  • CRUDE OIL

    82.79
    -0.02 (-0.02%)
     

  • GOLD FUTURES

    2,329.20
    -9.20 (-0.39%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • Bitcoin GBP

    51,377.70
    -1,861.33 (-3.50%)
     

  • CMC Crypto 200

    1,386.71
    -37.39 (-2.62%)
     

  • NASDAQ Composite

    15,712.75
    +16.11 (+0.10%)
     

  • UK FTSE All Share

    4,374.06
    -4.69 (-0.11%)
     
Money:

The five essential pieces of financial paperwork you must never lose

Mislaying key documents can cause real headaches, so it’s worth tracking down these most commonly-lost bits of paperwork

BUZZ-Medivation: Cancer therapy not as safe as AstraZeneca's

Reuters - UK Focus

** Drug developer's shares down 2 pct at $108.97 premarket

** Says its prostate cancer therapy Xtandi was not as safe as AstraZeneca Plc (NYSE: AZN - news) 's treatment Casodex in a mid-stage study

** Says 31 pct patients given Xtandi had serious adverse reactions compared with 23.3 pct patients who were given Casodex

** Says Xtandi increased the time patients survived without progression of the disease to 15.7 months, compared to 5.8 months among Casodex patients

** Up to Wednesday's close, the stock more than doubled since Xtandi was approved on Aug. 31 2012